Beijing Suncadia Pharmaceuticals Co., Ltd — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HRS-4029This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).	Accident vasculaire cérébral	Phase 2	À vérifier	China	À vérifier
SHR 3201 InjectionThis study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.	Alzheimer	Phase 1	À vérifier	China	À vérifier
SHR 3201 InjectionThis study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.	Alzheimer	Phase 1	À vérifier	China	À vérifier
HRS-4029This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).	Accident vasculaire cérébral	Phase 2	À vérifier	China	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
HRS-4029	Accident vasculaire cérébral	Phase 2	NCT07739160	The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients	RECRUITING
SHR 3201 Injection	Alzheimer	Phase 1	NCT07889349	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.